Eli Lilly Canada Inc. v. Novopharm Limited

Eli Lilly Canada Inc. v. Novopharm Limited

The appeal was dismissed because the Federal Court found Prothonotary Tabib did not err in law or palpably err in fact: she applied Rule 222(2) consistent with the train of inquiry concept, reasonably relied on prior U.S. productions and targeted additional disclosure where warranted (ordered review and further affidavit for post‑2001 clinical trial documents, review of certain pre‑1998 product liability documents and relevant prior art), and her discretionary case management choices attract deference; Novopharm failed to show a clearly wrong exercise of discretion or factual error.

Citation
2008 FC 281
Parties
Plaintiff (defendant by Counterclaim): Eli Lilly Canada Inc.; Plaintiff (defendant by Counterclaim): Eli Lilly and Company; Plaintiff (defendant by Counterclaim): Eli Lilly Company Limited; Plaintiff (defendant by Counterclaim): Eli Lilly SA; Defendant (plaintiff by Counterclaim): Novopharm Limited
Court
Federal Court
Jurisdiction
Canada
Judgment Date
3 March 2008
Procedural Posture
Patent Infringement; Counterclaim of Invalidity / Appeal From Prothonotary Decision on Interlocutory Discovery Motion for Further and Better Affidavit of Documents
Outcome
Appeal dismissed
Legal Topics
Affidavit of Documents, Train of Inquiry, Relevance, Standard of Review, Scope of Disclosure, Prior Art Disclosure
Source Language
English
Patent Law Civil Procedure Evidence/discovery Case Management Affidavit of Documents Train of Inquiry Relevance Standard of Review +2 more

Case Brief

Summary, issues, holding and outcome

More case intelligence is available

Unlock the full research layer for this judgment.

Full judgment text Legal principles 6 Authorities cited 11 Party arguments 2 Amounts and remedies 5
Sign in to unlock

Parties

Eli Lilly Canada Inc.

Plaintiff (defendant by Counterclaim)

Eli Lilly and Company

Plaintiff (defendant by Counterclaim)

Eli Lilly Company Limited

Plaintiff (defendant by Counterclaim)

Eli Lilly SA

Plaintiff (defendant by Counterclaim)

Novopharm Limited

Defendant (plaintiff by Counterclaim)

Procedural Posture

Patent Infringement; Counterclaim of Invalidity / Appeal From Prothonotary Decision on Interlocutory Discovery Motion for Further and Better Affidavit of Documents

Legal Issues

  1. 1 Whether prothonotary erred in refusing to order full production of documents prior to oral discovery
  2. 2 Proper application of Rule 222(2) and the Peruvian Guano "train of inquiry" test
  3. 3 Whether moving party must prove usefulness of unseen documents

Ratio Decidendi

The appeal was dismissed because the Federal Court found Prothonotary Tabib did not err in law or palpably err in fact: she applied Rule 222(2) consistent with the train of inquiry concept, reasonably relied on prior U.S. productions and targeted additional disclosure where warranted (ordered review and further affidavit for post‑2001 clinical trial documents, review of certain pre‑1998 product liability documents and relevant prior art), and her discretionary case management choices attract deference; Novopharm failed to show a clearly wrong exercise of discretion or factual error.

Court Disposition

Appeal dismissed

Orders

  • Appeal dismissed
  • Costs to the Plaintiffs in any event of the cause taxed at the upper scale of Column IV